PHA Pharmagest Interactive SA

EQUASENS: results of the votes on the resolutions submitted to the ordinary annual shareholders' meeting of 29 june 2023

EQUASENS: results of the votes on the resolutions submitted to the ordinary annual shareholders' meeting of 29 june 2023

Villers-lès-Nancy, 5 July 2023 - 6:00 p.m. (CET)

PRESS RELEASE

RESULTS OF THE VOTES ON THE RESOLUTIONS SUBMITTED

TO THE ORDINARY ANNUAL SHAREHOLDERS' MEETING

OF 29 JUNE 2023

Number of shares comprising the share capital: 15,174,125

Number of shares with voting rights: 15,032,834

Number of shares with voting rights possessed by shareholders presents or represented or having voted by mail: 13,046,120

That means a quorum of 86.78% of the 15,032,834 shares with voting rights: the Ordinary Annual General Meeting was able to deliberate.

The Ordinary Annual General Meeting was held on Thursday, 29 June 2023 at 5:30 p.m. at the Company’s headquarters and approved the separate parent company and consolidated financial statements for the 2022 financial year. The results of the votes on the resolutions proposed at this meeting by the Board of Directors were as follows:

Resolutions  



Results of the votes



 
  • RESOLUTION ONE
Approval of the annual financial statements		Resolution adopted by:
  • 13,044,237 votes in favour
  • 0 vote against
  • 1,883 abstentions
  • RESOLUTION TWO
Discharge of directors and discharge of the Statutory Auditors for the performance of their engagement		Resolution adopted by:
  • 12,943,792 votes in favour
  • 100,445 votes against
  • 1,883 abstentions
  • RESOLUTION THREE

    Approval of the consolidated financial statements
Resolution adopted by:
  • 13,044,237 votes in favour
  • 0 vote against
  • 1,883 abstentions
  • RESOLUTION FOUR
Appropriation of earnings, setting the dividend		Resolution adopted by:
  • 13,046,120 votes in favour
  • 0 vote against
  • 0 abstention
  • RESOLUTION FIVE
Agreements and commitments governed by Articles L. 225-38 of the French Commercial Code		Resolution adopted by (*):
  • 12,983,939 votes in favour
  • 62,072 votes against
  • 99 abstentions
  • RESOLUTION SIX
Renewal of Ms. Anne LHOTE's term of office as Director		Resolution adopted by:
  • 10,706,967 votes in favour
  • 2,339,153 votes against
  • 0 abstention
  • RESOLUTION SEVEN
Renewal of Ms. Céline GRIS's term of office as Independant Director		Resolution adopted by:
  • 11,112,739 votes in favour
  • 1,933,381 votes against
  • 0 abstention
  • RESOLUTION EIGHT
Renewal of Ms. Émilie LECOMTE's term of office as Director		Resolution adopted by:
  • 10,723,209 votes in favour
  • 2,322,911 votes against
  • 0 abstention
  • RESOLUTION NINE
Appointment of a new Director		Resolution adopted by:
  • 12,902,756 votes in favour
  • 143,364 votes against
  • 0 abstention
  • RESOLUTION TEN
Appointment of a new Statutory Auditor		Resolution adopted by:
  • 13,040,577 votes in favour
  • 5,543 votes against
  • 0 abstention
  • RESOLUTION ELEVEN
Approval of the information on the compensation of corporate officers paid in or granted for fiscal 2022 and mentioned in Article L. 22-10-9 of the French Commercial Code		Resolution adopted by:
  • 12,095,451 votes in favour
  • 950,669 votes against
  • 0 abstention
  • RESOLUTION TWELVE
Approval of the components of compensation paid in 2022 to Mr. Thierry CHAPUSOT, Chairman of the Board of Directors		Resolution adopted by:
  • 13,033,420 votes in favour
  • 12,700 votes against
  • 0 abstention
  • RESOLUTION THIRTEEN
Approval of the components of compensation paid in 2022 to Mr. Dominique PAUTRAT, Chief Executive Officer		Resolution adopted by:
  • 10,746,386 votes in favour
  • 2,299,734 votes against
  • 0 abstention
  • RESOLUTION FOURTEEN
Approval of the components of compensation paid in 2022 to Mr. Denis SUPPLISSON, Deputy Chief Executive Officer and then Chief Executive Officer		Resolution adopted by:
  • 10,592,005 votes in favour
  • 2,454,115 votes against
  • 0 abstention
  • RESOLUTION FIFTEEN
Approval of the components of compensation paid in 2022 to Mr. Grégoire DE ROTALIER, Deputy CEO		Resolution adopted by:
  • 10,592,005 votes in favour
  • 2,454,115 votes against
  • 0 abstention
  • RESOLUTION SIXTEEN
Approval of the compensation policy for the Chairman of the Board of Directors for 2023		Resolution adopted by:
  • 13,033,420 votes in favour
  • 12,700 votes against
  • 0 abstention
  • RESOLUTION SEVENTEEN
Approval of the compensation policy for Mr. Denis SUPPLISSON, Chief Executive Officer, for 2023		Resolution adopted by:
  • 10,759,416 votes in favour
  • 2,286,704 votes against
  • 0 abstention
  • RESOLUTION EIGHTEEN
Approval of the compensation policy for Mr. Grégoire de ROTALIER, Deputy Chief Executive Officer, for 2023		Resolution adopted by:
  • 10,759,416 votes in favour
  • 2,286,704 votes against
  • 0 abstention
  • RESOLUTION NINETEEN
Approval of the compensation policy for Directors		Resolution adopted by:
  • 13,044,420 votes in favour
  • 1,700 votes against
  • 0 abstention
  • RESOLUTION TWENTY
Setting total annual compensation for Directors for 2023		Resolution adopted by:
  • 13,044,420 votes in favour
  • 1,700 votes against
  • 0 abstention
  • RESOLUTION TWENTY-ONE
Authorisation by the Company to repurchase its own shares		Resolution adopted by:
  • 11,101,214 votes in favour
  • 1,944,906 vote against
  • 0 abstention
  • RESOLUTION TWENTY-TWO
Powers for formalities		Resolution adopted by:
  • 13,046,120 votes in favour
  • 0 vote against
  • 0 abstention

(*) After deduction of excluded voting rights

Financial Calendar:

  • Publication of H1 2023 Revenue: 3 August 2023, after French market closure.



About

Founded more than 35 years ago, Equasens Group, which now has more than 1,200 employees in Europe, is the leading publisher of software solutions for the healthcare industry in terms of the diversity of its business applications and market share.

Equasens Group’s specialised business applications facilitate the day-to-day work of healthcare professionals and their teams, working in private practice, collaborative medical structures or healthcare establishments. The Group also provides comprehensive support to healthcare professionals in the transformation of their profession by developing electronic equipment, digital solutions and healthcare robotics, as well as financing and training adapted to their specific needs.

And reflecting the spirit of its tagline " technology for a more human experience", the Group is a leading provider of interoperability solutions that improve coordination between healthcare professionals, their communications and data exchange resulting in better patient care and a more efficient healthcare system.

Listed on Euronext Paris™ - Compartment A

Indexes: MSCI GLOBAL SMALL CAP - GAÏA Index 2020 - CAC® SMALL and CAC® All-Tradable

Included in the Euronext Tech Leaders segment and the European Rising Tech label

Eligible for the Deferred Settlement Service (“Service à Règlement Différé” - SRD) and equity savings accounts invested in small and mid caps (PEA-PME)

ISIN: FR 0012882389 – Ticker Code: EQS

Get all the news about the Equasens Group and on

CONTACTS

Analyst and Investor Relations:

Chief Administrative and Financial Officer: Frédérique SCHMIDT

Tel. +33 (0)3 83 15 90 67 -

Media Relations:

FIN’EXTENSO - Isabelle APRILE

Tel. +33 (0)6 17 38 61 78 -   

Attachment



EN
05/07/2023

Underlying

PHAPharmagest Interactive SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pharmagest Interactive SA

Arnaud Riverain
  • Arnaud Riverain
PHA PHARMAGEST INTERACTIVE SA
11/24/23 November 24, 2023 4 FR
 PRESS RELEASE
Free
PHA Pharmagest Inte...

EQUASENS: Acquisition of the German company ADV and creation of PHARMA...

EQUASENS: Acquisition of the German company ADV and creation of PHARMAGEST Germany Villers-lès-Nancy, 23 November 2023 - 6:00 p.m. (CET) PRESS RELEASE Acquisition of the German company ADVand creation of PHARMAGEST Germany EQUASENS, in partnership with ARZ HAAN, a German market leader for services and software solutions for healthcare providers, acquires ADV (Apotheken Datenverarbeitung GmbH & Co. KG), which becomes PHARMAGEST Germany, through a holding company 6%-held by ARZ HAAN and 94%-held by EQUASENS. PHARMAGEST Germany will invest in developing technology and technical building bl...

November 23, 2023 1 EN
 PRESS RELEASE
Free
PHA Pharmagest Inte...

EQUASENS : Acquisition de l’allemand ADV et naissance de PHARMAGEST Ge...

EQUASENS : Acquisition de l’allemand ADV et naissance de PHARMAGEST Germany Villers-lès-Nancy, le 23 novembre 2023 – 18:00 (CET) COMMUNIQUE DE PRESSE Acquisition de l’allemand ADV et naissance de PHARMAGEST Germany EQUASENS, en association avec ARZ HAAN, un des leaders sur le marché de la Santé en Allemagne, acquiert au travers d’une Holding détenue à 6% par ARZ HAAN et 94% par EQUASENS, la société allemande ADV (Apotheken Datenverarbeitung GmbH & Co. KG) qui devient PHARMAGEST Germany. PHARMAGEST Germany investira dans le développement de briques technologiques et techniques ainsi que ...

November 23, 2023 1 EN
Arnaud Riverain
  • Arnaud Riverain
PHA Pharmagest Inte...

EQUASENS - CA T3 : Le Ségur perturbe le marché / Achat - Obj. 94,6 € -...

CA T3 stable à 50,1 M€                          / 9 mois +6% à 153,7 M€. Pharmagest T3 -1% (36,8 M€)      / 9 mois +6% ; Axigate Link T3 +6% (7,4 M€)      / 9 mois +6% ; E-Connect T3 +23% (3,6 M€)       / 9 mois +13% ; Medical Solutions -24% (1,8 M€)   / 9 mois +0%; Acquisition à venir d’ici la fin de l’année.

PHA PHARMAGEST INTERACTIVE SA
11/10/23 November 10, 2023 4 FR
 PRESS RELEASE
Free
PHA Pharmagest Inte...

Equasens: Q3 2023 revenue

Equasens: Q3 2023 revenue Villers-lès-Nancy, 9 November 2023 - 6:00 p.m. (CET) PRESS RELEASE Q3 2023 revenue Q3 2023 revenue: stable year-on-year at €50.1mGrowth impacted by: The completed deployment of solutions under the Ségur French Digital Healthcare investment programme:Adverse market conditions affecting Pharmacy sector. In €m20222023Change2023 / 2022Q149.456.3+14% (*)Q2 54.256.3 4 %Q3 (unaudited) 50.1 50.10 %9 month YTD 153.7162.7 6 % (*) Strong growth in Q1 reflecting a favourable comparison base (restructuring of the electronic labelling activity). ____________ : The PHARM...

November 9, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch